Genetic Technologies Limited
GNTLF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.04 | 0.70 | 0.11 |
| FCF Yield | -66.80% | -42.68% | -17.24% | -20.31% |
| EV / EBITDA | -1.26 | -1.38 | -3.10 | -1.88 |
| Quality | ||||
| ROIC | -429.43% | -51.05% | -27.76% | -26.67% |
| Gross Margin | 40.37% | 58.10% | 70.23% | -18.02% |
| Cash Conversion Ratio | 0.81 | 0.83 | 0.79 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.62% | 97.92% | 122.41% | 274.34% |
| Free Cash Flow Growth | 0.29% | -69.22% | 17.03% | -20.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.65 | 1.54 | 2.89 |
| Interest Coverage | -236.53 | -205.53 | -316.20 | -412.79 |
| Efficiency | ||||
| Inventory Turnover | 18.21 | 13.30 | 0.81 | 4.69 |
| Cash Conversion Cycle | -41.25 | -36.34 | -762.83 | 98.93 |